Ken Griffin Decibel Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$1.86 - $3.54 $40,315 - $76,729
-21,675 Reduced 1.2%
1,787,311 $3.66 Million
Q3 2022

Nov 14, 2022
BUY
$3.82 - $5.61 $63,709 - $93,563
16,678 Added 0.93%
1,808,986 $6.26 Million

About Decibel Therapeutics, Inc.

DBTX Quotes by TradingView
  • Ticker DBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,964,500
  • Description
  • Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to...
More about DBTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email